The Role of Chemotherapy in the Treatment of Primary Tumors of the Central Nervous System

References

• Boring C C, Squires T S, Tong T. Cancer Statistics, 1992. Ca 1992; 42: 19–43
   Google Scholar
• Greig N H, Reis L G, Yanick F, Rapaport S I. Increasing annual in- cidence of primary malignant brain tumors in the elderly. J Natl Cancer Inst 1990; 82: 1621–1624
   PubMed Web of Science ®Google Scholar
• Lossignol D, Grossman S A, Sheidler V R, et al. Familial clustering of malignant astrocytomas. J Neuro-oncol 1990; 9: 139–145
   PubMed Web of Science ®Google Scholar
• Osman M, Grossman S A, Griffin C, et al. Primary brain tumors in spouses and relatives: A report from the National Familial Brain Tumor Registry. Proc Am Soc Clin Oncol 1992; 11: 149
   Google Scholar
• Ikizler Y., van Meyel D, MacDonald D, et al. Gliomas in families: Coincidence or clue?. The 9th International Conference on Brain Tumor Research and Treatment. 1991; 5
   Google Scholar
• Crawford J, Cohen H J. Relationship of cancer and aging. Clin Geriatr Med 1987; 3: 419–432
   PubMedGoogle Scholar
• Kernohan J W, Mabon R F, Svien H J, Adson A W. A simplified classification of gliomas. Proc Staff Meet Mayo Clin 1949; 24: 71–75
   PubMed Web of Science ®Google Scholar
• Ringertz N. “Grading” of gliomas. Acta Pathol Microbiol Scand 1950; 27: 51–64
   PubMedGoogle Scholar
• WHO Working Group. March 31, 1990
   Google Scholar
• Daumas-Duport C, Scheithauer B, O'Fallen J, Kelly P. Grading of astrocytomas: A simple and reproducible method. Cancer 1988; 62: 2152–2165
   PubMed Web of Science ®Google Scholar
• Hoshino T., Nasahima T, Cho K G, et al. S phase fraction of human brain tumors in situ measured by uptake of bromodeoxyuridine. Int J Cancer 1986; 38: 369–374
   PubMed Web of Science ®Google Scholar
• Earle K M, Rentschler E H, Snodgrass S R. Primary intracranial neoplasms. Prognosis and classification of 513 verified cases. J Neuropathol Exp Neurol 1957; 16: 321–331
   PubMed Web of Science ®Google Scholar
• Burger P C, Vogel S. The brain: Tumors. Surgical Pathology of the Nervous System and Its Coverings, P C Burger, S Vogel. Wiley, New York, 224–458
   Google Scholar
• Sheline G E. Radiotherapy for high grade gliomas. Int J Radiat Oncol Biol Phys 1990; 18: 793–804
   PubMed Web of Science ®Google Scholar
• Sheline G E. Radiation therapy for tumors of the central nervous system in childhood. Cancer 1975; 35: 957–964
   PubMed Web of Science ®Google Scholar
• Bloom H JG, Walsh L S. Tumors of the central nervous system. Cancer in Children, Clinical Management, H JG Bloom, J Lemerle, M K Neidhardt. Springer-Verlag, New York 1975; 93–119
   Google Scholar
• Marsa G W, Profert J C, Rubinstein L C, et al. Radiation therapy in the treatment of childhood astrocytic gliomas. Cancer 1973; 32: 646–654
   PubMed Web of Science ®Google Scholar
• Leibel S A, Sheline G E, Wars W M, et al. The role of radiation therapy in the treatment of astrocytomas. Cancer 1975; 35: 1551–1557
   PubMed Web of Science ®Google Scholar
• Bloom H JG, Walsh L S. Tumors of the central nervous system. Cancer in Children, Clinical Management, H JG Bloom, J Lemerle, M K Neidhardt. Springer-Verlag, New York 1975; 93–119
   Google Scholar
• Oshini T, Sher P B, Posner J B, Shapiro W R. Capillary permeability factor secreted by malignant brain tumors. Role in peritumoral brain edema and possible mechanism for anti-edema effect of glucocorticoids. J Neurosurg 1990; 72: 245–251
   PubMed Web of Science ®Google Scholar
• Greig N H. Chemotherapy of brain metastases: Current status. Cancer Treat Rev 1984; 11: 157–186
   PubMed Web of Science ®Google Scholar
• Kelly P J, Daumas-Duport C, Scheithauer B W, et al. Stereotactic histologic correlations of computed tomography-magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987; 62: 950–959
   Google Scholar
• Walker M D, Alexander E, Hunt W E, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 1978; 49: 333–356
   PubMed Web of Science ®Google Scholar
• Wilson C B, Gutin P H, Boldrey E B, et al. Single-agent chemotherapy of brain tumors. Arch Neurol 1976; 33: 739
   PubMed Web of Science ®Google Scholar
• Fewer D, Wilson C B, Boldrey E B, et al. Phase II study of 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of brain tumors. Cancer Chemother Rep 1972; 56: 421
   PubMedGoogle Scholar
• Trojanowski T, Peszyniski J., Turowski K, et al. Quality of survival of patients with brain gliomas treated with postoperative CCNU and radiation therapy. J Neurosurg 1989; 70: 18–23
   PubMed Web of Science ®Google Scholar
• Levin V A, Resser D, McGrath L, et al. PCNU treatment for recurrent malignant gliomas. Cancer Treat Rep 1984; 68: 969
   PubMedGoogle Scholar
• Roosne N, Kiwit J C, Lins E, et al. Adjuvant intraarterial chemotherapy with nimustine in the management of World Health Organization grade IV gliomas of the brain. Experience at the Department of Neurosurgery of Dusseldorf University. Cancer 1989; 64: 1984–1994
   PubMed Web of Science ®Google Scholar
• Walker M D, Green S B, Byar D P, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980; 303: 1323–1329
   PubMed Web of Science ®Google Scholar
• Kumar A VR, Renaudin J, Wilson C B, et al. Procarbazine hydrochloride in the treatment of brain tumors. J Neurosurg 1974; 40: 365
   PubMed Web of Science ®Google Scholar
• Rodriguez L A, Prados M, Silver P, et al. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 1989; 64: 2420–2423
   PubMed Web of Science ®Google Scholar
• Schold S C, Friedman H S, Bjornsson T D, et al. Treatment of patients with recurrent primary brain tumors with AZQ. Neurology 1984; 34: 615
   PubMed Web of Science ®Google Scholar
• Taylor S A, McCracken J D, Eyre H J, et al. Phase II study of aziridinylbenzoquinone (AZQ) in patients with central nervous system malignancies: A Southwest Oncology Group study. J Neurooncol 1985; 3: 131–135
   PubMed Web of Science ®Google Scholar
• Prados M D, Rodriguez L, Seager M, et al. Phase II study of spirohydantoin mustard for the treatment of recurrent malignant gliomas. Cancer Treat Rep 1987; 71: 1105–1106
   PubMedGoogle Scholar
• Alavi J B, Schoenfeld, Skeel R T, et al. Phase II trial of spirogermanium and vindesine in malignant glioma. Am J Clin Oncol 1989; 12: 8–10
   PubMed Web of Science ®Google Scholar
• Newton H B, Page M A, Junck L, Greenberg H S. Intra-arterial cisplatin for the treatment of malignant gliomas. J Neuro-oncol 1989; 7: 39–45
   PubMed Web of Science ®Google Scholar
• Calvo F A, Dy C, Henriquez I, et al. Postoperative radical radio- therapy with concurrent weekly intra-arterial cisplatin for treatment of malignant glioma: A pilot study. Radiother Oncol 1989; 14: 83–88
   PubMed Web of Science ®Google Scholar
• Mahaley M S, Hipp S W, Dropcho E J, et al. Intracarotid cisplatin chemotherapy for recurrent gliomas. J Neurosurg 1989; 70: 371–378
   PubMed Web of Science ®Google Scholar
• Yung W K, Mechtler L, Gleason M J. Intravenous carboplatin for recurrent malignant gliomas: A phase II study. J Clin Oncol 1991; 9: 860–864
   PubMed Web of Science ®Google Scholar
• Twelves C J, Ash C M, Miles D W, et al. Activity and toxicity of carboplatin and iproplatin in relapsed high-grade glioma. Cancer Chemother Pharmacol 1991; 27: 481–483
   PubMed Web of Science ®Google Scholar
• Poisson M, Pereon Y, Chiars J, Delattre J Y. Treatment of recurrent malignant supratentorial gliomas with carboplatin (CB-DCA). J Neuro-oncol 1991; 10: 139–144
   PubMed Web of Science ®Google Scholar
• Roosne N, Kiwit J C, Lins E, et al. Adjuvant intraarterial chemotherapy with nimustine in the management of World Health Organization grade IV gliomas of the brain. Experience at the Department for Neurosurgery of Dusseldorf University. Cancer 1989; 64: 1984–1994
   PubMed Web of Science ®Google Scholar
• Loew F, Papavero L. The intra-arterial route of drug delivery in the chemotherapy of malignant brain tumors. Adv Tech Stand Neurosurg 1988; 16: 51–79
   PubMedGoogle Scholar
• Gerosa M A, Di Stefano E, Olivi A. VM-26 monotherapy trial in the treatment of recurrent supratentorial gliomas: Preliminary report. Surg Neurol 1981; 15: 128–134
   PubMed Web of Science ®Google Scholar
• Gutin P H, Wilson C B, Kumar A RV, et al. Phase II study of procarbazine, CCNU, vincristine combination chemotherapy in the treatment of malignant brain tumors. Cancer 1975; 35: 1398
   PubMed Web of Science ®Google Scholar
• Levin V A, Wara Wm, Davis R L, et al. Phase III comparison of chemotherapy with BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiation therapy with hydroxyurea to patient with malignant gliomas. J Neurosurg 1985; 63: 218
   PubMed Web of Science ®Google Scholar
• Levin V A, Silver P, Hannigan J, et al. Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6g61 final report. Int J Radiat Oncol Biol Phys 1990; 18: 321–324
   PubMed Web of Science ®Google Scholar
• Neuwalt E A, Howieson J, Frenkel E P, et al. Therapeutic efficacy of multi-agent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 1986; 19: 573–582
   PubMed Web of Science ®Google Scholar
• Shapiro W R, Woorhies R M, Hiesiger E M, et al. Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: A quantitative autoradiographic study. Cancer Res 1988; 48: 694–701
   PubMed Web of Science ®Google Scholar
• Kessinger A. High dose chemotherapy with autologous bone marrow rescue for high grade gliomas of the brain: A potential for improvement in therapeutic results. Neurosurgery 1984; 15: 747–50
   PubMed Web of Science ®Google Scholar
• Giannone L, Wolff S N. Phase II treatment of central nervous system gliomas with high-dose etoposide and autologous bone marrow transplantation. Cancer Treat Rep 1987; 71: 759–761
   PubMedGoogle Scholar
• Johnson D B, Thompson J M, Corwin J A, et al. Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation. J Clin Oncol 1987; 5: 783–789
   PubMed Web of Science ®Google Scholar
• Bergvall U. Temporal course of contrast medium enhancement in differential diagnosis of intracranial lesions with computer tomography. Advances in Cerebral Angiography, G Salamon. Springer-Verlag, Berlin 1975; 346–348
   Google Scholar
• Burman S, Rosenbaum A E. Rationale and techniques for intravenous enhancement in computed tomography. Radiol Clin North Am 1982; 20: 15–22
   PubMed Web of Science ®Google Scholar
• Hayman L A, Evans R A, Hinck V C. Delayed high iodine dose contrast computed tomography: Cranial neoplasms. Radiology 1980; 136: 677–684
   PubMed Web of Science ®Google Scholar
• Norman D, Stevens E A, Wings S D, et al. Quantitative aspects of contrast enhancement in cranial computed tomography. Radiology 1978; 129: 683–688
   PubMed Web of Science ®Google Scholar
• Shalen P R, Hayman L A, Wallace S, et al. Protocol for delayed contrast enhancement in computed tomography of cerebral neoplasia. Radiology 1981; 139: 397–402
   PubMed Web of Science ®Google Scholar
• Hoshino T. Therapeutic implications of brain tumor cell kinetics. Modern concepts in brain tumor therapy: Laboratory and clinical investigations. Dept. Health, Education and Welfare, Bethesda, MD 1977; 29–36, Natl Cancer Inst Monograph 46
   Google Scholar
• Grossman S A, Wharam M, Shiedler V, et al. BCNU/cisplatin followed by radiation in poor prognosis patients with high grade astrocytomas. Proc Am Soc Clin Oncol 1992; 11: 149
   Google Scholar
• Levin V A, Kabra P M, Freeman-Dove M A. Pharmacokinetics of intracarotid artery 14C-BCNU in the squirrel monkey. J Neurosurg 1978; 48: 587–593
   PubMed Web of Science ®Google Scholar
• Rosenblum M K, Delattre J Y, Shapiro W R. Fatal necrotizing encephalopathy complication treatment of malignant gliomas with intra-arterial BCNU and irradiation: A Pathological study. J Neuro-oncol 1989; 7: 269–281
   PubMed Web of Science ®Google Scholar
• Blacklock J B, Wright D C, Dedrick R L, et al. Drug streaming during intra-arterial chemotherapy. J Neurosurg 1986; 64: 284–291
   PubMed Web of Science ®Google Scholar
• Saris S C, Blasberg R G, Carson R E, et al. Intravascular streaming during carotid artery infusions. Demonstration in humans and reduction using diastole-phased pulsatile administration. J Neurosurg 1991; 74: 763–772
   PubMed Web of Science ®Google Scholar
• Shook D R, Beaudet L M, Doppman J L. Uniformity of intracarotid drug distribution with diastole-phased pulsed infusion. J Neurosurg 1987; 67: 726–731
   PubMed Web of Science ®Google Scholar
• Brem H. Polymers to treat brain tumors. Biomaterials 1990; 11: 699–710
   PubMed Web of Science ®Google Scholar
• Grossman S A, Reinhard C, Colvin O M, et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 1992; 76: 640–647
   PubMed Web of Science ®Google Scholar
• Brem H, Mahaley M S, Jr., Vick N A, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 1991; 74: 441–446
   PubMed Web of Science ®Google Scholar
• Dohrmann F J, Farwell J R, Flannery J T. Ependymomas and ependymoblastomas in children. J Neurosurg 1976; 45: 273–283
   PubMed Web of Science ®Google Scholar
• Goldwein J W, Glauser T A, Packer R J, et al. Recurrent intracranial ependymomas in children. Survival, patterns of failure, and prognostic factors. Cancer 1990; 66: 557–563
   PubMed Web of Science ®Google Scholar
• Levin V A, Edwards M S, Wara W M, et al. 5-Fluorouracil and CCNU followed by hydroxyurea, misonidazole and irradiation of brain stem gliomas: A pilot study of the Brain Tumor Research Center and the Children's Cancer Group. Neurosurgery 1984; 14: 679
   PubMed Web of Science ®Google Scholar
• Levin V A, Edwards M S, Wara W M, et al. 5-Fluorouracil and CCNU followed by hydroxyurea, misonidazole and irradiation of brain stem gliomas: A pilot study of the Brain Tumor Research Center and the Children's Cancer Group. Neurosurgery 1984; 14: 679
   PubMed Web of Science ®Google Scholar
• Goldwein J W, Leahy J M, Packer R J, et al. Intracranial ependymomas in children. Int J Radiat Oncol Biol Phys 1990; 19: 1497–1502
   PubMed Web of Science ®Google Scholar
• Strauss L C, Killmond T M, Carson B S, et al. Efficacy of post- operative chemotherapy using cisplatin plus etoposide in young children with brain tumors. Med Pediatr Oncol 1991; 19: 16–21
   PubMedGoogle Scholar
• Sheline G E, Boldrey E, Karlsberg P, Phillips T L. Therapeutic considerations in tumors affecting the central nervous system: Oligodendrogliomas. Radiology 1964; 82: 84–89
   PubMed Web of Science ®Google Scholar
• Chin H W, Hazel J J, Kim T H, Webster J H. Oligodendrogliomas. I. A Clinical study of cerebral oligodendrogliomas. Cancer 1980; 45: 1458–1466
   PubMed Web of Science ®Google Scholar
• Bullard D E, Rawlings C E, Phillips B. Oligodendroglioma-An analysis of the value of radiation therapy. Cancer 1987; 60: 2179–2188
   PubMed Web of Science ®Google Scholar
• Shaw E G, Scheithaouer B W, O'Fallon J R, et al. Oligodendrogliomas: The Mayo Clinical Experience. J Neurosurg 1992; 78: 428–434
   Google Scholar
• Frosina G, Rossi O, Arena G, et al. O6-alkylguanine-DNA alkyltransferase activity in human brain tumors. Cancer Lett 1990; 55: 153–158
   PubMed Web of Science ®Google Scholar
• Saarinen U M, Pihko H, Makipernaa A. High-dose thiotepa with autologous bone marrow rescue in recurrent malignant oligodendroglioma: A case report. J Neuro-oncol 1990; 9: 57–61
   PubMed Web of Science ®Google Scholar
• Levin V A, Sheline G E. Gutin PH: Neoplasms of the central nervous system. Cancer: Principles and Practice of Oncology, 3rd ed, V DeVita, S Hellman, S A Rosenberg. JB Lippincott, Philadelphia 1989; 1588
   Google Scholar
• Cairncross J G, Macdonald D R. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol 1988; 23: 360–364
   PubMed Web of Science ®Google Scholar
• MacDonald D R, Gaspar L E, Cairncross J G. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 1990; 27: 573–574
   PubMed Web of Science ®Google Scholar
• Tait D M, Thornton-Jones H, Bloom H J, et al. Adjuvant chemotherapy for medulloblastoma The first multi-center controlled trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 1990; 26: 464–469
   PubMed Web of Science ®Google Scholar
• Evans A E, Jenkin R D, Sposto R, et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine and prednisone. J Neurosurg 1990; 72: 572–582
   PubMed Web of Science ®Google Scholar
• Krischer J P, Fagab A H, Kun L, et al. Nitrogen mustard, vincristine, procarbazine and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. J Neurosurg 1991; 74: 905–909
   PubMed Web of Science ®Google Scholar
• Garton G R, Schomberg P J, Scheithauer B W, et al. Medulloblastoma-Prognostic factors and outcome of treatment: Review of the Mayo Clinic experience. Mayo Clin Proc 1990; 65: 1077–1086
   PubMed Web of Science ®Google Scholar
• Tarbell N J, Loeffler J S, Silver B, et al. The change in patterns of relapse in medulloblastoma. Cancer 1991; 68: 1600–1604
   PubMed Web of Science ®Google Scholar
• Belza M G, Donaldson S S, Steinberg G K, et al. Medulloblastoma: Freedom from relapse longer than 8 years-A therapeutic cure?. J Neurosurg 1991; 75: 575–582
   PubMed Web of Science ®Google Scholar
• Bloom H J, Bessell E M. Medulloblastoma in adults: A review of 47 patients treated between 1952 and 1981. Int J Radiat Oncol Biol Phys 1990; 18: 763–772
   PubMed Web of Science ®Google Scholar
• Walker R, Allen J. Cisplatin in the treatment of recurrent childhood brain tumors. J Clin Oncol 1988; 6: 62–66
   PubMed Web of Science ®Google Scholar
• Crafts D, Levin V, Edwards M S, et al. Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine. J Neurosurg 1978; 49: 589–592
   PubMed Web of Science ®Google Scholar
• Cangir A, Van Eys J, Berry D. Combination chemotherapy with MOPP in children with recurrent brain tumors. Med Pediatr Oncol 1978; 4: 253–261
   PubMedGoogle Scholar
• Bleyer W, Pendegrass T, Millstein J, et al. Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rational for preradiation chemotherapy. J Clin Oncol 1987; 5: 1221–1231
   PubMed Web of Science ®Google Scholar
• Forbes A R, Goldberg I D. Radiation therapy in the treatment of meningioma: The Joint Center for Radiation Therapy experience 1970 to 1982. J Clin Oncol 1984; 2: 1139–1143
   PubMed Web of Science ®Google Scholar
• Hochberg F H, Miller D C. Primary CNS lymphomas. J Neurosurg 1988; 68: 835–853
   PubMed Web of Science ®Google Scholar
• Gilbert M R, Harding B L, Grossman S A. Methotrexate neurotoxicity: In vitro studies using cerebellar explants from rats. Cancer Res 1989; 49: 2502–2505
   PubMed Web of Science ®Google Scholar
• Moynihan T J, Grossman S A, Troncoso J C, Phillips P. A laboratory model of human, treatment induced leukoencephalopathy. Proc Am Soc Clin Oncol 1992; 11: 149
   Google Scholar
• Green S B, Byar D P, Walker M D, et al. Comparisons of carmustine, procarbazine and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 1983; 67: 121–132
   PubMedGoogle Scholar
• Stewart D J, Grahovac Z, Benoit B, et al. Intracarotid chemotherapy with a combination of 1,3-bis(2-chlorethyl)-1-nitrosourea (BCNU), cis-diaminedichloroplatinum (cisplatin), and 4″-O-demethyl-I -O-(4,6-O-2-thenylidene-beta-D-glucoppryanosyl) epipodophyllotoxin (VM-26) in the treatment of primary and metastatic brain tumors. Neurosurgery 1984; 15: 828–833
   PubMed Web of Science ®Google Scholar
• Rosenthal J M, Robins H I, Finlay J, et al. Eight-drugs-in-one-day chemotherapy in post irradiated adult patients with malignant gliomas. Med Pediatr Oncol 1989; 17: 471–476
   PubMedGoogle Scholar
• Rosenthal J M, Robins H I, Finlay J, et al. Eight-drugs-in-one-day: Chemotherapy administered before and after radiotherapy to adult patient with malignant gliomas. Cancer 1989; 63: 2475–2481
   PubMed Web of Science ®Google Scholar
• Milanesi I, Silvani A, Munari L, et al. Preliminary data by cis- platin and etoposide using in primary glioblastoma. J Neurosurg Sci 1990; 34: 279–282
   PubMedGoogle Scholar
• Corden B J, Strauss L C, Killmond T, et al. Cisplatin, ara-C and etoposide (PAE) in the treatment of recurrent childhood brain tumors. J Neuro-oncol 1991; 11: 57–63
   PubMed Web of Science ®Google Scholar
• Coyle T, Baptista J, Winfield J, et al. Mechlorethamine, vin- cristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults: A phase II study. J Clin Oncol 1990; 8: 2014–2018
   PubMed Web of Science ®Google Scholar
• Prados M, Rodriguez L, Chamberlain M, et al. Treatment of recurrent gliomas with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and alpha-difluoromethylornithine. Neurosurgery 1989; 24: 806–809
   PubMed Web of Science ®Google Scholar
• Shapiro W R, Green A B, Burger P C, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg 1989; 71: 1–9
   PubMed Web of Science ®Google Scholar
• Bleehen N M, Freedman L S, Stenning S P. A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party. Int J Radiat Oncol Biol Phys 1989; 16: 1077–1081
   PubMed Web of Science ®Google Scholar
• Longee D C, Friedman H S, Albright R E, et al. Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine. J Neurosurg 1990; 72: 583–588
   PubMed Web of Science ®Google Scholar
• Yung W K, Harris M I, Brunner J M, Feun L G. Intravenous BCNU and AZQ in patient with recurrent malignant gliomas. J Neuro-oncol 1989; 7: 237–40
   PubMed Web of Science ®Google Scholar